马来酸噻吗洛尔用于婴幼儿血管瘤的研究进展

Research progress of timolol maleate in treatment of infantile hemangioma

婴幼儿血管瘤是婴幼儿常见的一种良性肿瘤,虽然一部分病变能够自然消退,但对于中高风险的婴幼儿血管瘤仍然需要积极治疗。马来酸噻吗洛尔是一种非选择性β受体阻滞剂,在临床上已经逐渐成为口服普萘洛尔的替代治疗,克服了口服全身不良反应的缺点,相比之下具有更好的有效性和安全性。本文简要综述马来酸噻吗洛尔应用于婴幼儿血管瘤治疗的作用机制及相关进展,以期为临床优化用量和剂型提供更多依据。

Infantile hemangioma is a common benign tumor in infants and young children.Although some lesions can be naturally subsided,active treatment is needed for middle-and high-risk infantile hemangioma.Tiamolol maleate is a nonselective beta receptor blocker,which has gradually become an alternative treatment for oral propranolol in clinical practice,which overcomes the shortcomings of oral systemic adverse reactions,and has better efficacy and safety in comparison.This article briefly reviews the mechanism and progress of timolol maleate in treatment of infantile hemangioma,in order to provide more basis for clinical optimization of dosage and dosage form.